January 31, 2025
The European Medicines Agency (EMA) announced it will review new safety data on the Alzheimer’s disease drug Leqembi (lecanemab). This follows a prior decision to recommend […]
January 31, 2025
The US Food and Drug Administration (FDA) has approved suzetrigine 50 mg tablets (Journavx, Vertex Pharmaceuticals), a first-in-class nonopioid analgesic for treatment of adults with moderate-to-severe […]
January 30, 2025
TOPLINE: Multiple sclerosis (MS) is associated with a 26% higher risk for mental illness during pregnancy and a 33% higher risk in the first postpartum year […]
January 29, 2025
Two separate clinical trials of dementia care programs report negative results in terms of patient neuropsychiatric symptoms and caregiver strain or distress, but the news may […]
January 29, 2025
Results of six recent trials of endovascular treatment (EVT) for patients with large-core ischemic stroke (LCIS) provide strong evidence for the benefit of this intervention compared […]
January 29, 2025
A novel biomarker signature may offer a more objective way of predicting pain sensitivity, new research suggested. Investigators utilized the biomarker, which consisted of two measures […]
January 29, 2025
Before the advent of the amyloid hypothesis in the 1990s, the cholinergic hypothesis offered key clues to the etiology of Alzheimer’s disease. Concentrated in the basal […]
January 27, 2025
Many Alzheimer’s experts were dismayed — but not surprised — when the Alzheimer’s Association stated that the disease could be diagnosed on the basis of pathology […]
January 27, 2025
MUMBAI (Reuters) – One person is believed to have died in India’s Maharashtra state in an outbreak of Guillain-Barre syndrome (GBS) – a neurological disease that […]